Bayerische Motoren Werke ADR (BMWYY)
29.20
+0.00 (0.00%)
OP · Last Trade: May 14th, 11:42 PM EDT
Detailed Quote
| Previous Close | 29.20 |
|---|---|
| Open | - |
| Bid | - |
| Ask | - |
| Day's Range | N/A - N/A |
| 52 Week Range | 25.15 - 37.52 |
| Volume | 0 |
| Market Cap | - |
| PE Ratio (TTM) | - |
| EPS (TTM) | - |
| Dividend & Yield | N/A (N/A) |
| 1 Month Average Volume | - |
Chart
News & Press Releases
BioMedNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Hits FDA Milestone and Expands Strategic Partnerships in Q1 Update
HeartBeam (NASDAQ: BEAT) reported Q1 2025 results highlighted by successful completion of the VALID-ECG pivotal study, supporting its 510(k) submission for 12-lead ECG synthesis software and confirming productive ongoing FDA discussions. The company launched an Early Access Program, signed a strategic partnership with AccurKardia to integrate its FDA-cleared AccurECG(TM) software, added two new U.S. patents to bring its IP total to 20, appointed CEO Robert Eno to its board, and raised $11.5 million through a public offering to support commercialization plans.
Via Investor Brand Network · May 14, 2025
BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Prices $5 Million Public Offering with Institutional Investor
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company focused on brain and central nervous system cancers, has priced a “reasonable best efforts” public offering with a single healthcare-focused institutional investor, raising approximately $5 million in gross proceeds. The offering includes 3,952,570 shares of common stock at $1.265 per share and accompanying Series F warrants to purchase an equal number of shares at $1.14 per share, exercisable immediately and valid for five years. A.G.P./Alliance Global Partners is acting as the sole placement agent. Proceeds will be used for working capital and general corporate purposes. Closing is expected on or about May 14, 2025.
Via Investor Brand Network · May 14, 2025
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Advances Phase 3 Alzheimer’s Trial and Expands Conference Presence in Q1
Annovis Bio (NYSE: ANVS) initiated its pivotal Phase 3 clinical trial in early Alzheimer’s disease during Q1 2025, with enrollment now underway for up to 760 participants to assess buntanetap’s symptomatic and disease-modifying effects over 18 months. The company also secured a new U.S. patent for buntanetap and participated in several key scientific and investor conferences, including Oppenheimer’s 35th Annual Healthcare Life Sciences Conference and AD/PD(TM) 2025 in Vienna. Cash and equivalents rose to $22.2 million as of March 31, 2025, while R&D expenses fell year-over-year to $5.0 million.
Via Investor Brand Network · May 14, 2025
Study Links Higher Consumption of Ultra-Processed Foods to Heightened Psoriasis Risk
A recently conducted study has found a strong link between the intake of ultra-processed foods (UPFs) and a higher risk of developing psoriasis. The findings of this research appeared in the Nutrients journal.
Via Investor Brand Network · May 13, 2025
Nutriband Inc. (NASDAQ: NTRB) Pioneers Innovative Approach to Opioid Crisis with Game-Changing Transdermal Patch
As the opioid crisis continues to challenge public health systems, the need for innovative solutions has become increasingly apparent. Rather than relying solely on restrictive measures, companies such as Nutriband (NASDAQ: NTRB) are exploring technological advancements to mitigate abuse while ensuring patient access to necessary medications. Nutriband’s development of AVERSA(TM) Fentanyl, an abuse-deterrent transdermal patch, exemplifies this forward-thinking approach ( https://ibn.fm/jhHMY ).
Via Investor Brand Network · May 13, 2025
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Secures Orphan Drug Designation Transfer for TPI 287 in Brain Cancer Indications
CNS Pharmaceuticals (NASDAQ: CNSP) announced the successful transfer of Orphan Drug Designation from Cortice Biosciences for its lead asset TPI 287, covering gliomas, pediatric neuroblastoma, and progressive supranuclear palsy. TPI 287, a microtubule-stabilizing abeotaxane, has shown potential to cross the blood-brain barrier and demonstrated encouraging results in a Phase 1 glioblastoma trial, including 3 complete and 9 partial responses among 23 evaluable patients. The company plans to initiate a Phase 2 study by year-end 2025 and highlighted the potential benefits of Orphan status, including seven years of market exclusivity upon approval.
Via Investor Brand Network · May 13, 2025
Cox Automotive executive analyst Erin Keating said that the cost of new cars has been climbing steadily since President Trump announced auto tariffs.
Via Stocktwits · May 13, 2025
Known for its fast response times, advanced tools, and local expertise, Car Keyline has emerged as a trusted leader in mobile automotive locksmith services across Ewing Township and surrounding areas. As an AAA-approved and fully licensed provider, the family-run business specializes in dealer-level solutions for all vehicle types, including luxury and high-security models.
Via Get News · May 12, 2025
BioMedNewsBreaks — NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Report Q1 2025 Results on May 15
NRx Pharmaceuticals (NASDAQ: NRXP) announced it will release its first quarter 2025 financial results after market close on Thursday, May 15, 2025. The company will host a conference call at 4:30 p.m. ET the same day to discuss the results and provide a corporate update.
Via Investor Brand Network · May 12, 2025
Wandrith Motorcycle Journeys, winner of "Best Self-Guided Motorcycle Tours in New Zealand of 2025," introduces a new digital app while expanding its premium self-guided motorcycle tours across Aotearoa.
Via Press Release Distribution Service · May 12, 2025
Study Reveals Early Development of Pediatric Brain Tumors in Specialized Nerve Cells
Medulloblastoma is a commonly occurring pediatric brain cancer in kids and adolescents. The cancer develops within the cerebellum, the part of the brain responsible for coordinating movement and other functions. These tumors enlarge quickly, can grow into nearby tissues, and in some cases, can metastasize. The variations in these tumors make it challenging to find appropriate treatments.
Via Investor Brand Network · May 9, 2025
Nutriband Inc. (NASDAQ: NTRB) Innovating Abuse-Deterrent Drug Delivery in a Shifting Opioid Landscape
The opioid crisis remains a critical public health challenge in the U.S. and globally, prompting a series of new regulatory measures designed to improve safety and reduce misuse. In early 2025, the FDA approved Journavx (suzetrigine), a first-in-class non-opioid painkiller offering patients safer alternatives to opioids. Additionally, opioid manufacturers are now required to include prepaid mail-back envelopes for safe disposal of unused medications, while enhanced boxed warnings on opioid labels further reinforce the dangers of misuse, addiction, and overdose.
Via Investor Brand Network · May 9, 2025
The Chinese EV maker is gradually turning things around.
Via The Motley Fool · May 9, 2025
Eye Exam Could Help in Detecting Parkinson’s Disease Early, Study Suggests
New research suggests that a simple examination of the retina could provide an early diagnosis of Parkinson’s disease. Universite Laval researchers conducted this study and their findings appeared in the Neurobiology of Disease journal.
Via Investor Brand Network · May 8, 2025
BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Reports Q1 Results, Advances CNM-Au8 Toward Potential Accelerated Approval for ALS
Clene (NASDAQ: CLNN) announced first quarter 2025 financial results and progress on its CNM-Au8 program for ALS and MS. The company is preparing for a potential NDA submission under the FDA’s Accelerated Approval pathway for ALS in Q4 2025, supported by survival data and upcoming biomarker analysis. New data also showed CNM-Au8 significantly improved survival in patients with more severe ALS. In MS, Clene presented Phase 2 extension results demonstrating remyelination and neuronal repair. The company reported a Q1 net loss of $0.8 million on reduced expenses and $9.8 million in cash, funding operations into Q3 2025.
Via Investor Brand Network · May 8, 2025
BioMedNewsBreaks — Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Reports $4.8 Million Net Gain in 2024, Driven by Loan-to-Equity Conversion
Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharma company focused on inflammation and immunology treatments and CDMO services, reported a $4.8 million net gain for 2024, reversing a $6.5 million loss in 2023. The improvement was largely due to $14.8 million in financial income from a loan-to-equity conversion. The company posted $658,000 in revenue—its first ever—from its CDMO unit. R&D expenses remained steady at $5.6 million, while G&A costs dropped to $2.6 million. Cash and equivalents totaled $1.9 million at year-end.
Via Investor Brand Network · May 8, 2025
Roman Hu, once a prominent figure in Chinese-language television, has successfully transitioned into one of New Zealand's leading real estate agents. His journey from media to property sales is marked by dedication, adaptability, and a commitment to excellence.
Via AB Newswire · May 6, 2025
BioMedNewsBreaks — Kairos Pharma Ltd. (NYSE American: KAPA) to Participate in D. Boral Capital Global Conference on May 14
Kairos Pharma (NYSE American: KAPA) announced it will participate in the D. Boral Capital Inaugural Global Conference on May 14, 2025, at The Plaza Hotel in New York City. CEO and Chairman John Yu, MD, will host one-on-one meetings with investors from 9 a.m. to 3 p.m. ET.
Via Investor Brand Network · May 6, 2025
Study: Women with Lung Cancer Have Worse Outcomes Due to Genes Linked to Pregnancy
According to a study conducted recently at Memorial Sloan Kettering (MSK) Cancer Center, lung cancer co-opts some genes usually involved in helping fetuses to grow. The lung cancer leverages these genes to evade the immune system of the patient. The researchers found that because of this, women in whom these genes were activated tended to have poorer outcomes.
Via Investor Brand Network · May 6, 2025
Moorestown, NJ - InTown Auto Care - Euro Automotive Repair: Audi, BMW, Land Rover, Mercedes, Mini, Porsche, Volkswagen continues to set the standard for auto repair in South Jersey by delivering specialized services for Porsche vehicles and other premier European brands. Serving Moorestown and the surrounding Mount Laurel area, the repair shop has established a strong reputation among discerning vehicle owners who expect precision, transparency, and expert-level performance from their automotive technicians.
Via GetFeatured · May 6, 2025
From dropout to multi-business founder, Ethan Money rises to lead Boston's most trusted brands in pet care, luxury rentals, PR, and dog products.
Via Press Release Distribution Service · May 5, 2025
BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Appoints CEO Robert Eno to Board of Directors
HeartBeam (NASDAQ: BEAT) a medical technology company advancing personalized cardiac care, has appointed Chief Executive Officer Robert Eno to its Board of Directors, expanding the board from eight to nine members. Eno, who joined the company as president in January 2023 and became CEO in October 2024, brings over 30 years of medtech leadership experience, including launching disruptive technologies. His appointment comes as the company prepares for the commercial launch of its 3D ECG technology, pending FDA clearance of its 12-lead ECG synthesis software.
Via Investor Brand Network · May 5, 2025
May 4, 2025 -- Foreign Car Specialists with a Local Touch
Via 24-7 Press Release · May 4, 2025
EDP Automotive Services, Ltd. (250-383-0911) has announced its updated engine diagnosis and repair services for Victoria vehicle owners.
Via Press Release Distribution Service · May 2, 2025
Data Shows When Hospitals Exit MA Plans, Enrollees Also Leave
For a variety of reasons, hospitals can disagree with Medicare Advantage insurance providers and they part ways. When a hospital cancels or fails to renew its contract with a health insurer, the patients who had coverage with that insurer often have to choose between staying with that insurer and getting care from the shrinking network of providers or ditch the MA plan. Reports indicate that thousands of patients ditch MA plans once the health insurer and hospital fail to continue their relationship.
Via Investor Brand Network · May 2, 2025